Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Letetresgene autoleucel +/- pembrolizumab in RRMM
NCT03168438Phase 1Terminated
- Sponsor
- GSK
- Start
- Aug 2017
- Primary completion
- Jul 2020
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of letetresgene autoleucel in multiple myeloma (MM) (2 arms), sponsored by GSK. Primary endpoints: Number of Participants With Adverse Events and Serious Adverse Events up to 108 weeks, Number of Participants With Treatment Limiting Toxicities up to 3 weeks and 2 more. Started Aug 2017; status: terminated.
02
Drugs
letetresgene autoleucel
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03168438.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03168438.